The ExteNET trial found that neratinib, compared to a placebo, improved invasive disease-free survival (iDFS) in patients with HER2/HR+ early-stage breast cancer after neoadjuvant/adjuvant trastuzumab-based therapy [43]. The gene discussed is ERBB2; the disease is breast carcinoma.